Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2940147 | 1.00 | USP2 (0.35) | USP2TSHRHSD11B1 | |
| SCHEMBL10476558 | 1.00 | USP2 (0.35) | USP2TSHRHSD11B1 | |
| SCHEMBL14778689 | 0.85 | USP2 (0.32) | USP2TSHR | |
| SCHEMBL22735285 | 0.83 | USP2 (0.36) | USP2TSHR | |
| SCHEMBL17338724 | 0.83 | USP2 (0.36) | USP2TSHRHSD11B1 | |
| SCHEMBL28829135 | 0.83 | USP2 (0.36) | USP2TSHRHSD11B1 | |
| SCHEMBL17338723 | 0.83 | USP2 (0.36) | USP2TSHRHSD11B1 | |
| SCHEMBL12631054 | 0.82 | USP2 (0.37) | USP2TSHR | |
| SCHEMBL12631059 | 0.82 | USP2 (0.37) | USP2TSHR | |
| SCHEMBL4101469 | 0.79 | USP2 (0.33) | USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2431370-B1 | Monoacylated 1,2-diaminocycloalkanes | DAIICHI SANKYO CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| EP-1270557-B1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090270446-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090227789-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20060004009-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270446-A1 | DIAMINE DERIVATIVES | F2, TFPI, F3 | USP2 3114/4885TSHR 1514/4885HSD11B1 4590/4885 |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | USP2 3806/4885TSHR 312/4885HSD11B1 1142/4885 |
| US-20060004009-A1 | Ethylenediamine derivatives | F2, ECE1, MLLT1 | USP2 4389/4885TSHR 1606/4885HSD11B1 3847/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | USP2 3813/4885TSHR 299/4885HSD11B1 2197/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | USP2 3878/4885TSHR 516/4885HSD11B1 2283/4885 |
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | USP2 4035/4885TSHR 456/4885HSD11B1 2184/4885 |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | C1R, C9, F2 | USP2 2807/4885TSHR 186/4885HSD11B1 3154/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | USP2 3878/4885TSHR 516/4885HSD11B1 2283/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | USP2 4019/4885TSHR 411/4885HSD11B1 2068/4885 |
| US-20090227789-A1 | ETHYLENEDIAMINE DERIVATIVES | F2, ECE1, MLLT1 | USP2 4389/4885TSHR 1606/4885HSD11B1 3847/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | USP2 4317/4885TSHR 1769/4885HSD11B1 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.